このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Novonesis 過去の業績

過去基準チェック /06

Novozymesの収益は年間平均-1.3%の割合で減少していますが、 Chemicals業界の収益は年間増加しています。収益は年間13.1% 8.1%割合で増加しています。 Novozymesの自己資本利益率は2.6%であり、純利益率は9.3%です。

主要情報

-1.3%

収益成長率

-0.6%

EPS成長率

Chemicals 業界の成長	12.9%
収益成長率	8.1%
株主資本利益率	2.6%
ネット・マージン	9.3%
次回の業績アップデート	07 Nov 2024

Recent updates

収支内訳

Novonesis の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

OTCPK:NVZM.F 収益、費用、利益 ( )EUR Millions
日付	収益	収益	G+A経費	研究開発費
30 Jun 24	3,045	283	575	326
31 Mar 24	2,696	332	506	298
31 Dec 23	2,401	406	446	271
30 Sep 23	2,390	430	441	270
30 Jun 23	2,382	460	446	272
31 Mar 23	2,390	487	441	270
31 Dec 22	2,360	494	430	267
30 Sep 22	2,268	460	443	262
30 Jun 22	2,186	418	418	257
31 Mar 22	2,090	416	403	257
31 Dec 21	2,009	423	380	266
30 Sep 21	1,958	427	335	268
30 Jun 21	1,914	409	322	274
31 Mar 21	1,883	389	310	270
31 Dec 20	1,883	380	309	256
30 Sep 20	1,920	415	309	248
30 Jun 20	1,955	405	326	254
31 Mar 20	1,968	439	335	264
31 Dec 19	1,924	422	329	263
30 Sep 19	1,923	411	334	262
30 Jun 19	1,917	434	321	260
31 Mar 19	1,922	417	315	249
31 Dec 18	1,927	432	313	248
30 Sep 18	1,924	427	311	254
30 Jun 18	1,915	429	310	247
31 Mar 18	1,920	423	320	248
31 Dec 17	1,952	419	332	255
30 Sep 17	1,958	421	334	255
30 Jun 17	1,934	412	332	254
31 Mar 17	1,919	414	328	251
31 Dec 16	1,902	410	325	251
30 Sep 16	1,864	394	327	247
30 Jun 16	1,883	394	333	253
31 Mar 16	1,883	384	331	259
31 Dec 15	1,876	378	330	254
30 Sep 15	1,840	366	320	255
30 Jun 15	1,795	353	314	252
31 Mar 15	1,741	340	311	243
31 Dec 14	1,673	339	306	237
30 Sep 14	1,641	334	314	227
30 Jun 14	1,605	324	310	216
31 Mar 14	1,598	319	312	211
31 Dec 13	1,575	295	311	205
30 Sep 13	1,557	286	302	206

質の高い収益: NVZM.Fには€105.1M } という大きな一回限りの損失があり、過去 12 か月の財務実績が30th June, 2024に影響を及ぼしています。

利益率の向上: NVZM.Fの現在の純利益率 (16.9%)は、昨年(20.9%)よりも低くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: NVZM.Fの収益は過去 5 年間で年間1.3%減少しました。

成長の加速: NVZM.Fは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。

収益対業界: NVZM.Fは過去 1 年間で収益成長率がマイナス ( -17.7% ) となったため、 Chemicals業界平均 ( -24.2% ) と比較することが困難です。

株主資本利益率

高いROE: NVZM.Fの自己資本利益率 ( 2.6% ) は低いとみなされます。

Novonesis 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Novozymes A/S to Report First Half, 2023 Results on Aug 09, 2023

Novozymes A/S to Report Fiscal Year 2020 Results on Jan 01, 2021

Recent updates

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Novozymes A/S Announces Change to the Executive Leadership Team

Novozymes A/S Provides Earnings Guidance for the Year 2023

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report First Half, 2023 Results on Aug 09, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Novozymes A/S Provides Revenue Guidance for 2022

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

Novozymes A/S Reaffirms Sales Guidance for the Year 2021

Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada

Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development

Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc.

Novozymes A/S Announces Executive Appointments, Effective April 2021

Fmc Corporation Collaborates with Novozymes A/S to Co-Develop Enzyme Solutions

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Microbiome Labs.

Novozymes A/S (CPSE:NZYM B) entered into an agreement to acquire Microbiome Labs for $250 million

Novozymes A/S to Report Fiscal Year 2020 Results on Jan 01, 2021

Novozymes A/S Announces Executive Changes

Novozymes A/S Announces Executive Changes

Firmenich and Novozymes Partner for Great-Tasting Yogurt with Unprecedented Sugar Reduction Performance

Novozymes A/S (CPSE:NZYM B) acquired Precisionbiotics Group Limited for €80 million.

Novozymes Omits to Provide Outlook for Second Half and Full Year of 2020

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06